GlassScriptPhysician profile
Alan Mitchell Grossman
NPI 1699770289
$3,427.55
in general payments reported to CMS, 2019-2025
32 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $141 · 2021: $183 · 2022: $535 · 2023: $599 · 2024: $915 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $902.38 | 2020-2025 | |
| Kestra Medical Technology Services, INC. | $380.59 | 2022-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $363.68 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $236.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.07 | 2019-2025 | Jardiance |
| Amgen INC. | $167.09 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $147.74 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $125.66 | 2019-2024 | Xarelto |
| Abbott Laboratories | $94.21 | 2019-2022 | |
| Boston Scientific Corporation | $83.78 | 2019-2024 | Watchman Flx, Varithena Administration Pack |
| Sanofi-Aventis U.S. LLC | $67.68 | 2022-2024 | |
| Medtronic Vascular, INC. | $67.12 | 2019 | |
| Baxter Healthcare | $63.01 | 2022-2024 | Perclot |
| Atricure, INC. | $51.67 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $50.50 | 2024 | Arcalyst |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $48.85 | 2020-2025 | Wainua |
| Cleerly, INC. | $47.06 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Bardy Diagnostics, INC. | $45.00 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.31 | 2022 | |
| Gilead Sciences, INC. | $39.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.72 | 2022-2023 | |
| Heartflow, INC. | $27.58 | 2025 | |
| Astellas Pharma US INC | $21.24 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.08 | 2022 | |
| Genzyme Corporation | $18.91 | 2025 | |
| Philips North America LLC | $18.41 | 2024 | (Cm9) Amb Mon & Diag Und |
| Edwards Lifesciences Corporation | $17.26 | 2022 | |
| Abiomed | $15.77 | 2025 | |
| Novo Nordisk INC | $14.06 | 2024 | Wegovy |
| Preventice Services, LLC | $13.55 | 2021 | |
| G Medical Diagnostic Services, INC. | $12.81 | 2022 | |
| Lundbeck LLC | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Grossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.